Efficacy of single-agent apatinib on advanced colorectal cancer patients failed in second and above chemotherapy
SUN Peipei
ZHANG Long
ZHANG Tai
ZHANG Wenhua
SUN Zhen
WANG Fengwei
Abstract：Objective To observe the efficacy and side effects of apatinib on advanced colorectal cancer patients,who failed in second-line and above chemotherapy.Methods Fourteen Ⅳ stage colorectal cancer patients who failed in second-line and above chemotherapy from January 2016 to November 2016 were enrolled in this study.Patients received the starting dose of 425 mg of apatinib per day.The efficacy and side effects were observed.Results Among the 14 advanced colorectal cancer patients,there were 2 cases of PR,6 cases of SD and 6 cases of PD.The response rate was 14.3％,and the disease control rate was 57.1％.The median progressionfree survival was 78 days.The main side effects were hypertension,hand-foot syndrome,mucositis,anorexia,leukopenia,thrombopenia and proteinuria,mainly in grade 1-3.Conclusion For the Ⅳ stage colorectal cancer patients who failed in second-line and above chemotherapy,apatinib 425 mg per day has good effect,and side effects can be tolerated.
Keywords：Colorectal cancerApatinibEfficacySide effects
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 646-649 )